Wacker has reached a milestone by opening an mRNA competence center at its biotech site in Halle (Saale), Germany. The new facility enables the large-scale production of active ingredients based on messenger ribonucleic acid (mRNA), such as anti-Covid mRNA vaccines.

Wacker invested more than €100 million in this construction project, creating more than 100 jobs in Halle. Some of the new capacity will be made available to the German government as part of its pandemic-preparedness plan to rapidly supply Germany with vaccines as and when required.

With 300 guests from politics and business, as well as employees in attendance, Wacker hosted an opening ceremony for the new mRNA competence center on June 3.2024.

Expansion of Wacker’s Halle site into an mRNA competence center enables the company to produce mRNA actives on a large scale going forward. Four new production lines have more than tripled the site’s capacity, some of which will be available to the German government as part of its pandemic-preparedness program. The remaining production capacity is for other customers. The first contracts in this regard have already been signed.

“The opening of our mRNA competence center in Halle is a milestone for Wacker. This is where we will be producing active ingredients for the medicines of tomorrow—not only for the German government, but for other customers too,” said Wacker CEO Christian Hartel during the opening ceremony. “Our expertise in making mRNA vaccines will contribute to the fight against future pandemics. It has taken us just two years to build a high-tech production facility with an annual capacity of more than 200 million vaccine doses—an unrivaled achievement in this field, which demonstrates true German efficiency.”

Melanie Käsmarker, managing director, Wacker Biotech, said, “Medicine is making great strides thanks to mRNA technology, which isn’t just confined to vaccines. For instance, this technology gives us an opportunity to offer cancer patients targeted support going forward. Wacker Biotech bundles the Wacker Group’s biopharmaceutical activities and manufactures active ingredients in Halle and at other sites for market and clinical trials conducted by pharmaceutical companies. Based in Halle, we’ll be able to meet the globally rising demand for mRNA actives,” she added.

Among the guests invited to attend the opening of the mRNA competence center were Sven Schulze, Saxony-Anhalt’s Economic Affairs Minister, Armin Willingmann, Saxony-Anhalt’s Science Minister, and Carsten Schneider, member of the federal parliament and, in his capacity as minister of state, the German government’s official representative for eastern Germany.

Given the initial vaccine shortage during the coronavirus pandemic, the German government has secured the production and supply of vaccines for the future. Companies were able to apply for pandemic-preparedness contracts with the German government. As joint bidders for the production readiness of mRNA-based vaccines, Wacker and CordenPharma were among those companies awarded a contract. In the event of a new pandemic, Wacker and CordenPharma intend to produce 80 million vaccine doses a year within an extremely short time. The two companies will receive an annual stand-by fee for keeping production capacity and expertise available. The stand-by phase will last for at least five years.

Should the need arise, the German government will contact the developer of the specific mRNA vaccine that is required. Wacker and CordenPharma will then jointly produce this mRNA vaccine in line with the highest pharmaceutical quality standards. Most of the production steps will take place in Germany.

Biotechnology is a strategic growth field for Wacker. By 2030, Wacker Biosolutions plans to contribute around €1 billion to group sales. The development of the Halle site into a competence center for mRNA will aid this strategy. The next milestone is expected to be reached this year when a new biotechnology center goes on stream in Munich.